SPRO

Spero Therapeutics Inc

SPRO.US sperotherapeutics.com + Research + Basket
CIK 0001701108
Employees 25
Phone 857 242 1600
Fiscal year end December
IPO Nov 02, 2017
Address 675 Massachusetts Avenue, Cambridge, MA, United States, 02139
1.11
-0.06 (-5.13%)
USD · NASDAQ
52-week range
1.04
3.08
Trading at 3% of the 52-week range
Market Cap
68.13M
P/E Ratio
8.36
Forward P/E
0.00
Book Value
0.76
Div. Yield
N/A
% Institutions
18.26%
% Insiders
22.66%

1 Year

-52.4%

3 Year

+7.8%

10 Year

-90.3%
Description

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Actions

Add an action for SPRO.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Ms. Esther P. Rajavelu CEO, President, CFO, Chief Business Officer, Treasurer & Director 1979
Mr. Timothy Keutzer Chief Operating Officer 1968
Mr. John Raymond Senior Vice President of Finance & Business Operations NA
Dr. Debra Jeske Zack M.D., Ph.D. Chief Medical Officer 1957

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Feb 06, 2026 Esther Rajavelu N/A Sale 87.92K $2.36 $207.48K SEC
Feb 02, 2026 Esther Rajavelu N/A Sale 18.44K $2.20 $40.57K SEC
Nov 07, 2025 Esther Rajavelu N/A Sale 40.27K $2.37 $95.44K SEC
Aug 28, 2025 Ankit Mahadevia N/A Sale 6.57K $1.97 $12.95K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
GSK PLC 9.19M Jun 30, 2026 15.78% $3.37 0.00%
Pfizer Inc 2.36M Jun 30, 2026 4.06% $3.13 0.00%
Vanguard Capital Management, LLC 2.04M Jun 30, 2026 3.50% $0.00 13.13%
Renaissance Technologies Corp 947.90K Jun 30, 2026 1.63% $0.00 -20.29%
Alphabet Inc 889.98K Jun 30, 2026 1.53% $0.00 0.00%
Susquehanna International Group, LLP 759.29K Jun 30, 2026 1.30% $0.00 127.94%
BlackRock Inc 594.40K Jun 30, 2026 1.02% $0.00 37.21%
Geode Capital Management, LLC 566.33K Jun 30, 2026 0.97% $0.00 8.93%
Two Sigma Investments LLC 382.81K Jun 30, 2026 0.66% $0.00 -56.78%
Arrowstreet Capital Limited Partnership 332.97K Jun 30, 2026 0.57% $0.00 0.00%
Vanguard Fiduciary Trust Co 287.65K Jun 30, 2026 0.49% $0.00 8.91%
GSA Capital Partners LLP 285.91K Jun 30, 2026 0.49% $0.04 2.73%
Dimensional Fund Advisors, Inc. 274.82K Jun 30, 2026 0.47% $0.00 823.21%
The Goldman Sachs Group Inc 256.99K Jun 30, 2026 0.44% $0.00 0.00%
State Street Corp 214.75K Jun 30, 2026 0.37% $0.00 0.00%
Jane Street Group LLC 158.10K Jun 30, 2026 0.27% $0.00 48.66%
UBS Group AG 139.68K Jun 30, 2026 0.24% $0.00 4,542.07%
Bridgeway Capital Management, LLC 114.80K Jun 30, 2026 0.20% $0.00 0.00%
Northern Trust Corp 108.27K Jun 30, 2026 0.19% $0.00 -10.51%
Point72 Asset Management, L.P. 104.38K Jun 30, 2026 0.18% $0.00 74.93%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 1.40M 2.40% ▲ 0.00% Sep 30, 2026
2 Mackenzie GQE US Small Cap F8 497.13K 0.85% ▲ 0.00% Jul 31, 2026
3 iShares Micro-Cap ETF 144.24K 0.25% ▼ 0.69% Sep 30, 2026
4 Fidelity Total Market Index 107.71K 0.19% ▲ 0.00% Aug 31, 2026
5 Invesco NASDAQ Future Gen 200 ETF 98.35K 0.17% ▲ 0.00% Sep 30, 2026
6 Fidelity Extended Market Index 71.72K 0.12% ▼ 71.19% Aug 31, 2026
7 Fidelity Series Total Market Index 69.79K 0.12% ▲ 0.00% Aug 31, 2026
8 EA Bridgeway Ultra-Small Company Mkt ETF 63.94K 0.11% ▲ 0.00% Sep 30, 2026
9 Acuitas US Microcap Institutional 56.46K 0.10% ▲ 0.00% Jun 30, 2026
10 Bridgeway Omni Small-Cap Value N 50.00K 0.09% ▲ 0.00% Jun 30, 2026

Financial Highlights

▼
Market Cap: $68.13M
EBITDA: $7.16M
P/E Ratio: $8.36
PEG Ratio: $0.00
Book Value: $0.76
Earnings/Share: $0.14
Profit Margin: 15.71%
Operating Margin: 14.07%
ROA (TTM): 7.19%
ROE (TTM): 19.17%
Revenue (TTM): $47.00M
Revenue/Share (TTM): $0.83
Earnings Growth (YOY): 75.30%
Revenue Growth (YOY): -95.60%

Valuation Metrics

Enterprise Value: $17.66M
Trailing P/E: 8.36
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 58.23M
Shares Float: 47.10M
% Insiders: 22.66%
% Institutions: 18.26%
Shares Short: 840.53K
Shares Short (Prior Month): 794.51K
Short Ratio: 1.00
Short % Float: 1.74%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$59.62M
Gross Profit
subtotal
$59.62M
SG&A
adjust
$-21.18M
R&D
adjust
$-38.47M
Operating Income
subtotal
$-24.00K
Other / Non-Operating Items
adjust
$8.60M
Net Income
subtotal
$8.57M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SPRO.US!